Charles Schwab Investment Management Inc. Decreases Stock Holdings in Teleflex Incorporated (NYSE:TFX)

Charles Schwab Investment Management Inc. lowered its position in shares of Teleflex Incorporated (NYSE:TFX) by 6.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 398,678 shares of the medical technology company’s stock after selling 27,705 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Teleflex were worth $98,601,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TFX. Cromwell Holdings LLC raised its stake in shares of Teleflex by 59.0% during the third quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock valued at $33,000 after acquiring an additional 49 shares during the last quarter. Avior Wealth Management LLC increased its holdings in Teleflex by 190.6% during the 3rd quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company’s stock valued at $38,000 after purchasing an additional 101 shares during the period. Ashton Thomas Securities LLC bought a new position in Teleflex during the 3rd quarter valued at approximately $40,000. Canada Pension Plan Investment Board purchased a new stake in Teleflex in the 2nd quarter worth approximately $42,000. Finally, GAMMA Investing LLC grew its position in shares of Teleflex by 131.1% in the 3rd quarter. GAMMA Investing LLC now owns 171 shares of the medical technology company’s stock worth $42,000 after buying an additional 97 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Stock Down 1.9 %

TFX stock opened at $191.02 on Wednesday. The business has a 50 day moving average of $222.95 and a 200 day moving average of $222.87. The firm has a market cap of $8.87 billion, a PE ratio of 37.98, a price-to-earnings-growth ratio of 1.96 and a beta of 1.18. Teleflex Incorporated has a twelve month low of $185.66 and a twelve month high of $257.85. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, October 31st. The medical technology company reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.38 by $0.11. The firm had revenue of $764.40 million for the quarter, compared to analysts’ expectations of $768.68 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The company’s quarterly revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.64 earnings per share. On average, research analysts forecast that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be issued a $0.34 dividend. The ex-dividend date is Friday, November 15th. This represents a $1.36 annualized dividend and a yield of 0.71%. Teleflex’s dividend payout ratio (DPR) is presently 27.04%.

Analyst Upgrades and Downgrades

TFX has been the subject of a number of recent analyst reports. Truist Financial restated a “hold” rating and set a $227.00 target price (down previously from $255.00) on shares of Teleflex in a report on Monday, November 4th. Royal Bank of Canada cut their target price on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Stephens raised their price objective on shares of Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a report on Friday, November 1st. Finally, Mizuho lowered their target price on Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Teleflex currently has a consensus rating of “Moderate Buy” and a consensus target price of $259.25.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.